Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Journal subject
Affiliation country
Publication year range
1.
Clin Nephrol ; 90(5): 357-362, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30021694

ABSTRACT

A 69-year-old man presented with acute kidney injury, hypocomplementemia, antinuclear antibody, and anti-dsDNA antibody. He had no signs of systemic lupus erythematosus or Sjögren syndrome. He had not begun taking any new drugs in the preceding 6 months. Kidney biopsy revealed 13 glomeruli, 3 with global sclerosis. The remaining glomeruli showed slight mesangial proliferation. The interstitial inflammation was extensive, comprising mainly mature lymphocytes and plasma cells, neutrophils, and a few eosinophils. Remarkable granular and diffuse deposition of IgG and C1q was observed along the tubular basement membranes. Electron microscopy showed electron-dense deposits in the tubular basement membrane. Immunohistochemistry showed only 1 - 4 IgG4-positive plasma cells per high-power field and an IgG4/CD138 ratio of ~ 10%. He was treated with oral prednisolone 35 mg/day, and his kidney function gradually improved. This is a unique case that is not consistent with any known disease entities with immune complex-mediated tubulointerstitial nephritis.
.


Subject(s)
Glomerulonephritis, Membranoproliferative , Immune Complex Diseases , Nephritis, Interstitial , Neutrophils/immunology , Aged , Humans , Male
2.
Intern Med ; 59(7): 983-986, 2020 Apr 01.
Article in English | MEDLINE | ID: mdl-31866629

ABSTRACT

A 22-year-old woman had been diagnosed with idiopathic thrombocytopenic purpura (ITP) 5 years earlier. After undergoing splenectomy, she relapsed frequently following prednisolone tapering. She was complicated with minimal change nephrotic syndrome (MCNS) while taking 20 mg of prednisolone. Despite treatment with prednisolone, cyclosporin and low-density lipoprotein-apheresis, MCNS and ITP did not improve. We added rituximab in 4 weekly infusions of 375 mg/m2. MCNS and ITP were in complete remission. After administering rituximab once, all medicines were discontinued. No relapse had occurred by 50 months following the first rituximab administration. Rituximab affects steroid-resistant MCNS and ITP for a long time without complications.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Nephrotic Syndrome/drug therapy , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Rituximab/therapeutic use , Adult , Female , Humans , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL